On Jun. 4, 2021, Chimerix announced that the U.S. Food and Drug Administration (FDA) had granted TEMBEXAﾮ (brincidofovir) tablets and oral suspension approval for the treatment of smallpox. TEMBEXA was approved for adult and pediatric patients, including neonates.